Copyright
©The Author(s) 2017.
World J Hepatol. May 18, 2017; 9(14): 677-688
Published online May 18, 2017. doi: 10.4254/wjh.v9.i14.677
Published online May 18, 2017. doi: 10.4254/wjh.v9.i14.677
Table 1 Overview of the modified Delphi, 18-point quality assessment checklist for studies included in the review
Ref. | Yes response | No response | Partiel reported/ unclear | Assessment |
Fattovich et al[21] | 16 | 2 | 0 | High-quality |
Diago et al[7] | 15 | 2 | 1 | High-quality |
Apolinario et al[9] | 14 | 2 | 2 | High-quality |
Darling et al[31] | 14 | 1 | 3 | High-quality |
Lagging et al[34] | 14 | 3 | 1 | High-quality |
Al-Ashgar[19] | 13 | 3 | 2 | Low-quality |
Derbala et al[32] | 13 | 2 | 3 | Low-quality |
Kurelac et al[33] | 12 | 3 | 3 | Low-quality |
Table 2 Baseline total patient number, number of male patients, mean age, body mass index and ethnicity for the 8 included studies
Ref. | Patients | Mean age | BMI | Ethnicity | |||
Males | Total (n) | (yr) | (kg/m2) | Caucasian | African American | Asian | |
Apolinario et al[9] | 40 | 63 | 41 (± 9.3)5 | Information not provided | Information not provided6 | ||
1Lagging et al[34] | 169 | 2522 | 2529 | ||||
IL28B rs12979860 CC | 64 | 93 | 41.6 (± 10.1)5 | 25.1 (± 3.6)5 | |||
IL28B rs12979860 CT | 77 | 123 | 41.9 (± 9.5)5 | 25.0 (± 3.5)5 | |||
IL28B rs12979860 TT | 28 | 36 | 41.9 (± 11.4)5 | 25.0 (± 3.5)5 | |||
Diago et al[7] | 77 | 137 | 42 (± 9.7)5 | Information not provided | Information not provided | ||
Fattovich et al[21] | 133 | 2263 | 46 (± 11)5 | 24.7 (± 3.8)5 | 226 | ||
Kurelac et al[33] | 17 | 46 | 41.5 (± 12.4)5 | 23.7 (21.9-25)4 | 46 | ||
Darling et al[31] | 176 | 272 | 48.4 (± 7.4)5 | Information not provided | 138 | 134 | |
Darbala et al[32] | 144 | 159 | 46.47 (± 8.83)5 | 30.18 (± 5.05)5 | Information not provided7 | ||
Al-Ashgar et al[19] | 41 | 64 | 38.7 (± 11.5)5 | Information not provided | Information not provided8 |
Table 3 Hepatitis C virus-RNA and patient liver enzyme status for the 8 included studies
Ref. | HCV-RNA | Liver enzyme level | |||||
High viral load | Low viral load | All patients | AST | ALT | |||
n | Limit | n | Limit | ||||
Apolinario et al[9] | 28 | ≥ 6.3 log IU/mL5 | 35 | < 6.3 log IU/mL5 | 118 IU/L (± 64) $ | ||
1Lagging et al[34] | |||||||
IL28B rs12979860 CC | 6.3 log IU/mL (± 0.8)3 | Information not provided | |||||
IL28B rs12979860 CT | 6.1 log IU/mL (± 0.7)3 | ||||||
IL28B rs12979860 TT | 5.9 log IU/mL (± 0.8)3 | ||||||
Diago et al[7] | 85 | ≥ 5.7 log IU/mL5 | 52 | < 5.7 log IU/mL5 | 117.2 IU/L (± 81.6)3 | ||
Fattovich et al[21] | 147 | ≥ 5.6 log IU/mL5 | 5.74 log IU/mL (± 0.9)35 | 92 IU/L (± 78)3 | |||
Kurelac et al[33] | 5.55 log IU/mL (5.52-6.1)25 | Information not provided | |||||
Darling et al[31] | 6.66 log IU/mL (± 6.76)35 | 90.9 IU/L (72.9)3 | |||||
Darbala et al[32] | 4.95 log IU/mL (3.6-5.63)45 | 38 IU/L (27-51)4 | 51 IU/L (34-87)4 | ||||
Al-Ashgar et al[19] | 45 | ≥ 5.78 log IU/mL | 19 | < 5.78 log IU/mL5 | 67.5 IU/L (43.5-106.8)2 | 56.0 IU/L (32.0-86.0)2 |
Table 4 Genotype and liver fibrosis stage for the 8 included studies
Ref. | Genotype (n) | Method | Liver fibrosis stage | |||||||||
1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | 5 | 6 | ||
Apolinario et al[9] | 43 | 20 | Scheuer score | 28 | 35 | |||||||
Lagging et al[34]4 | 1701 | 231 | 491 | 111 | Ishak score | 11 | 61 | 65 | 30 | 15 | 20 | 14 |
IL28B rs12979860 CC | 44 | 13 | 33 | 3 | 3 | 18 | 27 | 11 | 5 | 12 | 5 | |
IL28B rs12979860 CT | 96 | 7 | 15 | 5 | 7 | 35 | 27 | 17 | 7 | 6 | 6 | |
IL28B rs12979860 TT | 30 | 3 | 1 | 3 | 1 | 8 | 11 | 2 | 3 | 2 | 3 | |
Diago et al[7] | 103 | 9 | 25 | Ishak score | 106 | 31 | ||||||
Fattovich et al[21] | 92 | 87 | 47 | Metavir2 | 121 | 21 | ||||||
Kurelac et al[33] | 46 | Ishak | 34 | 12 | ||||||||
Darling et al[31] | 272 | Ishak | 220 | 52 | ||||||||
Darbala et al[32] | 159 | Scheuer score | 109 | 50 | ||||||||
Ashgar et al[19] | 64 | Metavir | 343 | 10 3 |
Table 5 Overview of the treatment regimens for pegylated interferon in combination with ribavirin, for the 8 studies included, in relation to dose and duration
Ref. | Genotype | Duration | Interferon treatment | Ribavirin treatment | |
Apolinario et al[9] | Multi-centerpatients | 1 | 48 wk | 180 μg peg-INF-α-2a once weekly | 800 mg per day or 1000 mg < 75 kg, 1200 mg > 75 kg |
Non-1 | 24-48 wk | ||||
Out patiens | 1 | 48 wk | peg-INF-α2b 1.5 μg/kg per week | 1000-1200 mg per day | |
Non-1 | 24 wk | ||||
Lagging et al[34] | 1 | 6 wk1 | 180 μg peg-INF-α-2a once weekly | 1000 mg < 75 kg, 1200 mg > 75 kg per day | |
Diago et al[7] | 1 | 48 wk | peg-INF-α-2b 1.5 μg/kg per week or 180 μg peg-INF-α-2a/week | 1000 mg < 75 kg, 1200 mg > 75 kg per day | |
Non-1 | 24 wk | ||||
Fattovich et al[21] | 1 and 4 | 48 wk | peg-INF-α-2b 1.5 μg/kg per week or 180 μg peg-INF-α-2a/week | 800-1200 mg per day | |
2 and 3 | 24 wk | ||||
Kurelac et al[33] | 1 | 48 wk | peg-INF-α-2b 1.5 μg/kg per week | Weight based ribavirin treatment2 | |
Darling et al[31] | 1 | 48 wk | 180 μg peg-INF-α-2a once weekly | 1000-1200 mg per day | |
Derbala et al[32] | 4 | 48 wk | Peg-IFN once weekly3 | 1000 mg < 75 kg, 1200 mg > 75 kg per day | |
Al-Ashgar[19] | 4 | 48 wk | 180 μg peg-INF-α-2a once weekly | 1000 mg < 75 kg, 1200 mg > 75 kg |
Table 6 Overview of the marker distribution, in the four studied that supplied information on interleukin 28B single nucleotide polymorphism
Table 7 Overview of rapid virological response in the 3 studies providing information on baseline inducible protein-10’s, and hepatitis C virus RNA levels at week 4
Ref. | Patients (n) | IP-10 measurement method | Genotype (n) | Baseline IP-10 concentration, grouped by rapid virological response (pg/mL) | Overall RVR (n) | |||
RVR | Non-RVR | P-value | RVR | Non-RVR | ||||
Lagging et al[34] | 170 | ELISA (Quantikine, R and D systems, Minneapolis, MN, United States) | 1 (170) | 222 | 401 | P < 0.01 (median) | 33 | 137 |
1Fattovich et al[21] | 226 | ELISA (Quantikine, R and D systems, Minneapolis, MN, United States) | 1 (92) | 2.4 (± 0.28) | 2.6 (± 0.25) | P < 0.01 (log mean ± SD) | 172 | 108 |
2 (87) | 2.38 (± 0.31) | 2.3 (± 0.30) | P > 0.05 (log mean ± SD) | |||||
3 (47) | 2.45 (± 0.23) | 2.48 (± 0.39) | P > 0.05 (log mean ± SD) | |||||
Al-Ashgar et al[19] | 64 | ELISA (Quantikine, R and D systems, Minneapolis, MN, United States) | 4 (64) | 483.9 (± 261.6) | 609.9 (±424.3) | P > 0.05 (mean ± SD) | 12 | 52 |
Table 8 Overview of sustained viral response in the 8 studies providing information on baseline inducible protein-10’s, and hepatitis C virus-RNA levels 24 wk after end-of- treatment
Ref. | Patients (n) | IP-10 measurement method | Genotype (n) | Baseline IP-10 concentration, grouped by sustained virological response (pg/mL) | Overall SVR | |||
SVR | Non-SVR | P-value | SVR | Non-SVR | ||||
Apolinario et al[9] | 63 | ELISA (OptEIA, Pharmingen, San Diego, CA, United States) | 1 (43) | 245 (± 154) | 381 (± 138) | P < 0.05 (mean ± SD) | 36 | 27 |
Diago et al[7] | 137 | ELISA (Human immunoassay kit; BioSource Europe SA, Nivelles, Belgium | 1 (103) | 347 (± 197.4) | 500.6 (± 311.2) | P < 0.01 (mean ± SD) | 792 | 582 |
1 (103) | 332.4 (± 222.1) | 476.8 (± 305.3) | P < 0.01 (mean ± SD) | |||||
2 (9) | ||||||||
3 (25) | ||||||||
1Fattovich et al[21] | 226 | ELISA (Quantikine, R and D systems, Minneapolis, MN, United States ) | 1 (92) | 2.47 ± 0.23 | 2.65 ± 0.28 | P < 0.001 (log mean ± SD) | 2092 | 712 |
2 (87) | 2.37 ± 0.31 | 2.33 ± 0.35 | P > 0.05 (log mean ± SD) | |||||
3 (47) | 2.42 ± 0.21 | 2.67 ± 0.46 | P < 0.05a (log mean ± SD) | |||||
Kurelac et al[33] | 46 | ELISA (Quantikine, R and D systems, Minneapolis, MN, United States ) | 1 (46) | 185 (63-518) | 395.5 (111-926) | P < 0.0001 (median, range) | 26 | 20 |
Darling et al[31] | 272 | ELISA (Quantikine, R and D systems, Minneapolis, MN, United States ) | 1 (272) | 437 (± 31) | 704 (± 44) | P < 0.001 (mean ± SD) | 157 | 115 |
Derbala et al[32] | 159 | Luminex, Cytokine multiplex immunoassay kit (Merck Millipore, Billerica, MA, United States) | 4 (159) | Exact data not provided, only graphic presentation | P < 0.001 (median, IQR) | 98 | 61 | |
Al-Ashgar et al[19] | 64 | ELISA (Quantikine, R andD systems, Minneapolis, MN, United States ) | 4 (64) | 462 (± 282.6) | 840.4 (± 490.6) | P < 0.01 (mean ± SD) | 41 | 23 |
- Citation: Neesgaard B, Ruhwald M, Weis N. Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review. World J Hepatol 2017; 9(14): 677-688
- URL: https://www.wjgnet.com/1948-5182/full/v9/i14/677.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i14.677